Submit Deal

FAIRMOUNT FUNDS MANAGEMENT

Summary

Fairmount is a registered investment adviser with $1bn+ AUM dedicated to investing in promising new biotechnology companies with a focus on differentiated therapeutics, robust research organizations, and experienced management teams.

Deals Overview

Total Deals7

Valued Deals6

Total Value£ 1.05 B

Avg. Deal Size£ 176 M

Market Context

Senior Management

Peter Harwin
Partner

Sort

miragen therapeutics

HQ - United States

Biotechnology

28 Oct 2020

Investment Date

£ 70 M

Deal Value

zenas biopharma

HQ - United States

Biotechnology

7 Nov 2022

Investment Date

£ 103 M

Deal Value

apogee therapeutics

HQ - United States

Biotechnology

7 Dec 2022

Investment Date

£ 122 M

Deal Value

mirador therapeutics

HQ - United States

Pharmaceuticals

21 Mar 2024

Investment Date

£ 314 M

Deal Value

zenas biopharma

HQ - United States

Biotechnology

7 May 2024

Investment Date

£ 160 M

Deal Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy